FDA To Facilitate 4-AP Compassionate Use INDs For MS, Axelrad Says
FDA will ensure that multiple sclerosis patients taking 4-aminopyridine will continue to have the unapproved drug available through compassionate use INDs, Associate Director-Policy Jane Axelrad told the Pharmacy Compounding Advisory Committee July 14.
You may also be interested in...
FDA’s refuse-to-file letter for Firdapse in two ultra-rare neuromuscular disorders does not make judgments about the drug’s safety or efficacy, says Catalyst.
FDA has signaled that it will re-form its Pharmacy Compounding Drugs Advisory Committee, which was dissolved in 2002, as it deals with an ongoing meningitis outbreak related to compounded steroid injections. 2012 proved to be another busy year for the Oncologic Drugs Advisory Committee, but the full drug safety/risk management panel saw a significantly lighter workload than in recent years.
The agency has not set a meeting date for the Pharmacy Compounding Drugs Advisory Committee, defunct since 2002, in its tentative schedule, but has included 13 vacancies on the panel in its list of committees in need of new members.